<乌鸦传媒>Many With Cancer Predisposition Diseases Unaware of Genetic Status Moreover, a significant proportion do not qualify for genetic screening under current guidelines Apr 19, 2023
<乌鸦传媒>Risks Outweigh Benefits for BSO at Benign Hysterectomy in Younger Women It's less clear-cut for postmenopausal women, study authors say Apr 18, 2023
<乌鸦传媒>VTE Risk in Recurrent Ovarian Cancer Increases With More Lines of Chemotherapy Prospective study in heavily treated population is warranted, researcher says Mar 30, 2023
<乌鸦传媒>Novel Strategies Show Winning Potential in Ovarian Cancer High response rates in small studies of immuno-oncology combination, neoadjuvant olaparib Mar 28, 2023
<乌鸦传媒>CDK4/6 Inhibition Active in Recurrent Low-Grade Serous Ovarian Cancer Responses in a fourth of patients, clinical benefit in up to 90% Mar 26, 2023
<乌鸦传媒>OS Benefit Eludes Second-Line Niraparib Maintenance in Ovarian Cancer Significant PFS results demonstrated in NORA trial don't extend to overall survival Dec 17, 2022
<乌鸦传媒>FDA OKs First Antibody-Drug Conjugate for Platinum-Resistant Ovarian Cancer Mirvetuximab soravtansine produced responses in almost a third of patients in pivotal trial Nov 15, 2022
<乌鸦传媒>Pandemic Led to Surgical Delays in Gynecologic Cancers, and Worse Outcomes One in five patients experienced changes in their care plan Oct 04, 2022
<乌鸦传媒>Rucaparib a Winner for PFS, But Not for OS, in Recurrent Ovarian Cancer PARP inhibitor still has value as maintenance therapy, ARIEL3 investigator says Oct 01, 2022
<乌鸦传媒>'Potential Detrimental Effect' With Fourth-Line Olaparib in Ovarian Cancer Post-hoc data from SOLO3 show diverging results based on prior lines of therapy Sep 30, 2022
<乌鸦传媒>Maintenance PARP Inhibition Boosts OS in Two Ovarian Cancer Trials Results from SOLO-1 and PAOLA-1 show "clinically meaningful" long-term results with olaparib Sep 09, 2022
<乌鸦传媒>Worse OS With Rucaparib First in Trial of Recurrent, BRCA+ Ovarian Cancer A closer look at why PARP inhibitor's third-line indication was withdrawn Sep 09, 2022
<乌鸦传媒>Does PARP Inhibitor Maintenance Induce Platinum Resistance in Ovarian Cancer? Shorter progression-free interval with platinum chemotherapy after olaparib maintenance Sep 01, 2022
<乌鸦传媒>Nonselective Beta-Blockers May Improve Outcomes in Ovarian Cancer Lower all-cause, cancer-specific mortality in women who received the drugs around time of surgery Aug 29, 2022
<乌鸦传媒>Two Sides of Endosalpingiosis: Benign Growth or Harbinger of Cancer? Concurrent malignancy more than twice as common as compared with endometriosis, study showed Aug 06, 2022
<乌鸦传媒>Prosthetic Mesh May Stand in the Way of Further Abdominal Operations Prior incisional hernia repair associated with complications with later abdominal surgery Aug 04, 2022
<乌鸦传媒>Another Possible Use for Aspirin: Reducing Ovarian Cancer Risk Potential benefit seen in women with and without established cancer risk factors Jul 27, 2022
<乌鸦传媒>Drugmaker Pulls Third-Line PARP Inhibitor Approval in Ovarian Cancer Decision on rucaparib follows negative OS signal and "discussions" with FDA Jun 17, 2022
<乌鸦传媒>PARP Inhibitor Picks Up a Win in Frontline Maintenance for Ovarian Cancer Median PFS more than doubled with rucaparib after response to platinum-based chemotherapy Jun 07, 2022
<乌鸦传媒>New Clue to Risk of Peritoneal Cancer After Prophylactic Salpingo-Oophorectomy Women with BRCA variant and serous tubal intraepithelial carcinoma had a 34-fold greater risk Apr 05, 2022
<乌鸦传媒>Artificial Sweeteners Not So Sweet When It Comes to Cancer Risk Consumption of certain sugar alternatives linked to a 13% higher risk of developing cancer Mar 24, 2022
<乌鸦传媒>Intraperitoneal Carboplatin Boosts PFS in Ovarian Cancer Should the gynecologic oncology community reconsider IP therapy? Mar 22, 2022
<乌鸦传媒>Novel ADC Promising in Tough-to-Treat Ovarian Cancer Ocular AEs an issue with mirvetuximab in folate receptor alpha-high platinum-resistant disease Mar 20, 2022
<乌鸦传媒>Adjuvant Chemo Disappoints in Low-Grade Serous Ovarian Cancer Study suggests no improvement in overall survival Mar 19, 2022
<乌鸦传媒>Uterine Cancer Mortality Now Neck and Neck With Ovarian Cancer Advances in ovarian cancer, stagnation in uterine cancer, and "alarming" racial disparity Feb 09, 2022
<乌鸦传媒>A Better Option for Preserving Fertility in Gynecologic Cancer Patients? In vitro maturation can result in both embryos and oocyte vitrification, researcher says Oct 19, 2021
<乌鸦传媒>Christiane Amanpour's Ovarian Cancer and the Importance of Early Detection Renowned reporter calls on women to advocate for themselves Oct 11, 2021
<乌鸦传媒>Another Checkpoint Inhibitor Misses Mark in Ovarian Cancer No OS or PFS benefit with nivolumab versus chemotherapy for platinum-resistant disease Sep 24, 2021
<乌鸦传媒>Rechallenge With PARP Inhibitor Slows Relapsed Ovarian Cancer Benefits platinum-sensitive disease irrespective of BRCA, homologous repair status, study showed Sep 17, 2021
<乌鸦传媒>Third Dose a Charm in Israel? Door-to-Door 'Goons'; Cervids Catch COVID, Too! A daily roundup of news on COVID-19 and the rest of medicine Jul 30, 2021
<乌鸦传媒>COVID Vaccine Protection; 'Until You Die From the Cancer'; What's Palliative Care? News, features, and commentary about cancer-related issues Jun 10, 2021
<乌鸦传媒>Ovarian Cancer Screening Trial Still Sees No Death Reduction Researchers "disappointed" by long-term results of U.K. study of 200,000 postmenopausal women May 22, 2021
<乌鸦传媒>Report: Worst Hospitals for Unnecessary Procedures Lown Institute says report is the first to name hospitals with high rates of overuse May 04, 2021
<乌鸦传媒>Triage System Gets High Marks for Ovarian Cancer Debulking Surgery Key factors predicted threefold higher risk of 90-day mortality with primary surgery Mar 26, 2021
<乌鸦传媒>HIPEC Combo Doubles PFS in Advanced Ovarian Cancer Cisplatin/paclitaxel boosts outcomes without increasing complications in registry study Mar 26, 2021
<乌鸦传媒>Combo Tx Active in Recurrent, Platinum-Resistant Ovarian Cancer Ixabepilone plus bevacizumab yielded responses in a third of patients Mar 26, 2021
<乌鸦传媒>Androgen Receptor Inhibitor Active in Endometrial Cancer SGO: Apatinib for platinum-resistant ovarian cancer, pembrolizumab for advanced vulvar cancer Mar 22, 2021
<乌鸦传媒>Small Molecule Inhibitor Shows Promise in Resistant Ovarian Cancer Responses in 37% of patients with AVB-500, higher without prior bevacizumab Mar 21, 2021
<乌鸦传媒>Is MIS Viable for Interval Debulking in Ovarian Cancer? Retrospective study compared approach versus open surgery after neoadjuvant chemotherapy Mar 21, 2021
<乌鸦传媒>PARP Inhibitor Tops Chemo for Recurrent BRCA Ovarian Cancer Modest improvement in PFS with rucaparib but worse outcome for reversion mutation Mar 20, 2021
